Peer-reviewed veterinary case report
Afoxolaner chewables effectively treat demodicosis skin mites in dogs
By Lebon, Wilfried et al.·Published in Parasites & vectors·2018·Boehringer Ingelheim Animal Health, France·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of two formulations of afoxolaner (NexGard® and NexGard Spectra®) for the treatment of generalised demodicosis in dogs, in veterinary dermatology referral centers in Europe.
- Species:
- dog
Plain-English summary
A group of dogs with generalized demodicosis, a skin condition caused by Demodex mites, were treated with a chewable medication called afoxolaner (NexGard or NexGard Spectra). Over three months, the dogs received the treatment once a month, and the results were promising. The number of mites decreased significantly, with reductions of up to 98% by the end of the study. Additionally, the dogs showed improvements in their skin lesions and itching, indicating that the treatment was effective and well-tolerated.
People also search for: dog skin problems treatment · Demodex mites in dogs · NexGard for dog skin issues
Abstract
BACKGROUND: A multi-centre field trial was conducted to evaluate the efficacy of afoxolaner based chewables (NexGard® or NexGard Spectra®) for the treatment of generalised demodicosis caused by Demodex canis in dogs under field conditions in France, Italy and Poland. METHODS: Client-owned dogs, diagnosed positive for Demodex mites by pre-treatment skin scrapings and presenting clinical signs of generalised demodicosis were included. Dogs were orally treated with afoxolaner three times at monthly intervals. Of the 50 dogs enrolled, 48 completed the whole study. Efficacy of the treatments was assessed monthly by Demodex mite counts and physical examination with special regard to the severity and extension of skin lesions. RESULTS: Treatments were well tolerated in all dogs and resulted in a rapid reduction of mites, with all post-treatment mite counts significantly lower than baseline. The number of mites was reduced by 87.6%, 96.5% and 98.1% on Days 28, 56 and 84, respectively. In addition, the skin lesion severity and extent scores as well as the pruritus were all significantly lower at all post-treatment visits compared to the pre-treatment assessment. CONCLUSIONS: This clinical field study demonstrated that monthly administrations of afoxolaner in NexGard® or NexGard Spectra®, offered a convenient and reliable solution for the treatment of canine generalised demodicosis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30201031/